Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802)

Evaristo Maiello; Gabriele Di Maggio; Stefano Cordio; Saverio Cinieri; Francesco Giuliani; Salvatore Pisconti; Antonio Rinaldi; Antonio Febbraro; Tiziana Pia Latiano; Michele Aieta; Antonio Rossi; Daniele Rizzi; Massimo Di Maio; Giuseppe Colucci; Roberto Bordonaro

doi:10.1016/j.clcc.2020.01.003

Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802)

Evaristo Maiello, Gabriele Di Maggio, Stefano Cordio, Saverio Cinieri, Francesco Giuliani, Salvatore Pisconti, Antonio Rinaldi, Antonio Febbraro, Tiziana Pia Latiano, Michele Aieta, Antonio Rossi, Daniele Rizzi, Massimo Di Maio, Giuseppe Colucci, Roberto Bordonaro

Research output: Contribution to journal › Article › peer-review

Abstract

Bevacizumab plus either FOLFOX-4 (oxaliplatin, folinic acid, and infusional 5-fluorouracil) or XELOX-2 (capecitabine plus oxaliplatin) is among standard first-line treatment options in patients with metastatic colorectal cancer. This phase II randomized non-comparative trial evaluated the first-line combination of bevacizumab with either FOLFOX-4 or biweekly XELOX-2 in patients with metastatic colorectal cancer. Comparable response and a better tolerability for bevacizumab plus XELOX-2 was reported.

Original language	English
Pages (from-to)	109-115
Number of pages	7
Journal	Clinical Colorectal Cancer
Volume	19
Issue number	2
DOIs	https://doi.org/10.1016/j.clcc.2020.01.003
Publication status	Published - Jun 2020

Keywords

Capecitabine
Elderly
Fluoropyrimidine
Frail
Non-comparative

ASJC Scopus subject areas

Oncology
Gastroenterology

Access to Document

10.1016/j.clcc.2020.01.003

Fingerprint Dive into the research topics of 'Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802)'. Together they form a unique fingerprint.

Cite this

Maiello, E., Di Maggio, G., Cordio, S., Cinieri, S., Giuliani, F., Pisconti, S., Rinaldi, A., Febbraro, A., Latiano, T. P., Aieta, M., Rossi, A., Rizzi, D., Di Maio, M., Colucci, G., & Bordonaro, R. (2020). Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). Clinical Colorectal Cancer, 19(2), 109-115. https://doi.org/10.1016/j.clcc.2020.01.003

Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer : A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). / Maiello, Evaristo; Di Maggio, Gabriele; Cordio, Stefano; Cinieri, Saverio; Giuliani, Francesco; Pisconti, Salvatore; Rinaldi, Antonio; Febbraro, Antonio; Latiano, Tiziana Pia ; Aieta, Michele; Rossi, Antonio; Rizzi, Daniele; Di Maio, Massimo; Colucci, Giuseppe; Bordonaro, Roberto.

In: Clinical Colorectal Cancer, Vol. 19, No. 2, 06.2020, p. 109-115.

Research output: Contribution to journal › Article › peer-review

Maiello, E, Di Maggio, G, Cordio, S, Cinieri, S, Giuliani, F, Pisconti, S, Rinaldi, A, Febbraro, A, Latiano, TP , Aieta, M, Rossi, A, Rizzi, D, Di Maio, M, Colucci, G & Bordonaro, R 2020, 'Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802)', Clinical Colorectal Cancer, vol. 19, no. 2, pp. 109-115. https://doi.org/10.1016/j.clcc.2020.01.003

Maiello E, Di Maggio G, Cordio S, Cinieri S, Giuliani F, Pisconti S et al. Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). Clinical Colorectal Cancer. 2020 Jun;19(2):109-115. https://doi.org/10.1016/j.clcc.2020.01.003

Maiello, Evaristo ; Di Maggio, Gabriele ; Cordio, Stefano ; Cinieri, Saverio ; Giuliani, Francesco ; Pisconti, Salvatore ; Rinaldi, Antonio ; Febbraro, Antonio ; Latiano, Tiziana Pia ; Aieta, Michele ; Rossi, Antonio ; Rizzi, Daniele ; Di Maio, Massimo ; Colucci, Giuseppe ; Bordonaro, Roberto. / Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer : A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). In: Clinical Colorectal Cancer. 2020 ; Vol. 19, No. 2. pp. 109-115.

@article{b96434f61a6f452cbc16a25c61828712,

title = "Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802)",

abstract = "Bevacizumab plus either FOLFOX-4 (oxaliplatin, folinic acid, and infusional 5-fluorouracil) or XELOX-2 (capecitabine plus oxaliplatin) is among standard first-line treatment options in patients with metastatic colorectal cancer. This phase II randomized non-comparative trial evaluated the first-line combination of bevacizumab with either FOLFOX-4 or biweekly XELOX-2 in patients with metastatic colorectal cancer. Comparable response and a better tolerability for bevacizumab plus XELOX-2 was reported.",

keywords = "Capecitabine, Elderly, Fluoropyrimidine, Frail, Non-comparative",

author = "Evaristo Maiello and {Di Maggio}, Gabriele and Stefano Cordio and Saverio Cinieri and Francesco Giuliani and Salvatore Pisconti and Antonio Rinaldi and Antonio Febbraro and Latiano, {Tiziana Pia} and Michele Aieta and Antonio Rossi and Daniele Rizzi and {Di Maio}, Massimo and Giuseppe Colucci and Roberto Bordonaro",

year = "2020",

month = jun,

doi = "10.1016/j.clcc.2020.01.003",

language = "English",

volume = "19",

pages = "109--115",

journal = "Clinical Colorectal Cancer",

issn = "1533-0028",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer

T2 - A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802)

AU - Maiello, Evaristo

AU - Di Maggio, Gabriele

AU - Cordio, Stefano

AU - Cinieri, Saverio

AU - Giuliani, Francesco

AU - Pisconti, Salvatore

AU - Rinaldi, Antonio

AU - Febbraro, Antonio

AU - Latiano, Tiziana Pia

AU - Aieta, Michele

AU - Rossi, Antonio

AU - Rizzi, Daniele

AU - Di Maio, Massimo

AU - Colucci, Giuseppe

AU - Bordonaro, Roberto

PY - 2020/6

Y1 - 2020/6

N2 - Bevacizumab plus either FOLFOX-4 (oxaliplatin, folinic acid, and infusional 5-fluorouracil) or XELOX-2 (capecitabine plus oxaliplatin) is among standard first-line treatment options in patients with metastatic colorectal cancer. This phase II randomized non-comparative trial evaluated the first-line combination of bevacizumab with either FOLFOX-4 or biweekly XELOX-2 in patients with metastatic colorectal cancer. Comparable response and a better tolerability for bevacizumab plus XELOX-2 was reported.

AB - Bevacizumab plus either FOLFOX-4 (oxaliplatin, folinic acid, and infusional 5-fluorouracil) or XELOX-2 (capecitabine plus oxaliplatin) is among standard first-line treatment options in patients with metastatic colorectal cancer. This phase II randomized non-comparative trial evaluated the first-line combination of bevacizumab with either FOLFOX-4 or biweekly XELOX-2 in patients with metastatic colorectal cancer. Comparable response and a better tolerability for bevacizumab plus XELOX-2 was reported.

KW - Capecitabine

KW - Elderly

KW - Fluoropyrimidine

KW - Frail

KW - Non-comparative

UR - http://www.scopus.com/inward/record.url?scp=85079908915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079908915&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2020.01.003

DO - 10.1016/j.clcc.2020.01.003

M3 - Article

C2 - 32089455

AN - SCOPUS:85079908915

VL - 19

SP - 109

EP - 115

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 2

ER -